Advancements across various facets of the medical sector have occurred at a rapid pace over the past couple of decades, due to technological innovations and research activities. The development of new drugs for a range of medical diseases and conditions has shifted gears over the past few years due to which, the demand for biosimulation has witnessed unprecedented growth– a factor that is expected to boost the growth of the biosimulation market during the assessment period. Biosimulation is increasingly being used in drug discovery and drug development applications, including target identification & validation, lead identification & optimization, and pre-clinical testing of new drugs.
Players operating in the drug development sector are increasingly focusing on deploying various strategies to minimize monetary loss and financial costs upon failure of a drug therapy. At present, drug development companies and researchers continue to find the most effective way to bridge the gap between clinical medicine & drug development and patient response. Several new projects have entered the biosimulation market that primarily aim to improve drug development and delivery for a range of medical diseases and conditions. Advancements in the software technology and advent of artificial intelligence are likely to have a strong influence on the overall growth of the global biosimulation market during the assessment period.
At the back of these factors, the global biosimulation market is projected to reach a market value of US$ 7 Bn by the end of 2030. A number of market players are increasingly focusing on developing biosimulation platforms to gain a competitive edge in the current market landscape.
Recent advancements in the development of biomedical simulations have played an imperative role in boosting the overall growth of the global biosimulation market. Biosimulations are increasingly being used to assess diseases, engineer cells, and model cellular processes. Market players that are currently operating in the biosimulation market are focusing on enhancing the quality of biosimulations by introducing simulation models by leveraging tools and practicing utilization in software engineering. The model engineering trend has gained considerable momentum in the recent past due to which, the global biosimulation market is on the course to exhibit an impressive growth rate during the assessment period.
Progress in software engineering is expected to largely benefit the development of biosimulation models in terms of construction, design, testing, error checking, etc. Market players are anticipated to address the current underlying issues pertaining to biosimulation such as readability, reproducibility, and reuse. Advancements in model engineering techniques are likely to play an essential role in the overall development of the global biosimulation market during the assessment period.
Sensing the growing interest in biosimulation, a number of players involved in the current biosimulation market are focusing on expanding their operations and services to gain competitive edge. For instance, Switchback Medical, one of the top tier medical device contract design and manufacturing companies announced that the company is likely to expand its services by creating a new division– Switchback BioSim Innovations. With the expansion, the company aims to improve its market position by offering dynamic biosimualtion model development, physical training, and cell culture services.
In April 2020, OnScale and LEXMA entered a partnership– a move wherein both companies are expected to leverage AI and cloud simulation, and launch effective biosumualation solutions to improve patient outcome.
The outbreak of the novel COVID-19 pandemic is expected to have a low impact on the global biosimulation market. Research and development activities are likely to continue in full swing amid the COVID-19 crisis, as researchers and medical experts explore the potentials of biosimulation to curb the transmission of the novel coronavirus. Thus, the demand for biosimulation solutions and platforms is anticipated to witness steady growth.
Analysts’ Viewpoint
The global biosimulation market is expected to expand at an impressive CAGR of 13.3% during the forecast period. Advancements in technology, increasing focus on improving drug development & discovery, growing adoption of artificial intelligence, and rising emphasis on improving model engineering solutions are factors projected to drive the global market. In addition, research and development activities, along with increasing investments toward the same would play a key role in fueling the global biosimulation market growth during the assessment period.
The global biosimulation market was worth US$ 1.8 Bn and is projected to reach a value of US$ 7 Bn by the end of 2030
Biosimulation market is anticipated to grow at a CAGR of 13.3% during the forecast period
North America accounted for a major share of the global biosimulation market
Biosimulation market is driven by increase in adoption of biosimulation in drug discovery and development by regulatory bodies, rise in failure rates of drugs in the late clinical trial phases
Key players in the global biosimulation market include Certara, Dassault Systèmes S.A., Schrödinger, Inc., Simulations Plus, Inc., Rhenovia Pharma, Advanced Chemistry Development, Inc., Insilico Biotechnology AG, Physiomics plc, Genedata AG, and Rosa & Co. LLC
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biosimulation Market
4. Market Overview
4.1. Definition
4.2. Market Indicators
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biosimulation Market Value (US$ Mn) Forecast, 2018–2030
4.5. Global Biosimulation Market Outlook
5. Key Insights
5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.2. Technological Advancements
5.3. Healthcare Industry Overview
5.4. Key Industry Events
6. Global Biosimulation Market Analysis and Forecast, by Offering Type
6.1. Introduction
6.2. Global Biosimulation Market Value Share Analysis, by Offering Type
6.3. Global Biosimulation Market Value Forecast, by Offering Type, 2018–2030
6.3.1. Software
6.3.1.1. PK/PD Modeling & Simulation
6.3.1.2. PBPK Modeling & Simulation
6.3.1.3. Trial Simulators
6.3.1.4. Molecular Modeling
6.3.1.5. Others
6.3.2. Services
6.4. Global Biosimulation Market Attractiveness Analysis, by Offering Type
7. Global Biosimulation Market Analysis and Forecast, by Application
7.1. Introduction
7.2. Global Biosimulation Market Value Share Analysis, by Application
7.3. Global Biosimulation Market Value Forecast, by Application, 2018–2030
7.3.1. Drug Discovery
7.3.1.1. Target Identification & Validation
7.3.1.2. Lead Identification & Optimization
7.3.2. Drug Development
7.3.2.1. Pre-clinical Testing
7.3.2.2. Clinical Trial
7.3.3. Others
7.4. Global Biosimulation Market Attractiveness Analysis, by Application
8. Global Biosimulation Market Analysis and Forecast, by End-user
8.1. Introduction
8.2. Global Biosimulation Market Value Share Analysis, by End-user
8.3. Global Biosimulation Market Value Forecast, by End-user, 2018–2030
8.3.1. Contract Research Organization
8.3.2. Pharmaceutical & Biotechnology Companies
8.3.3. Research Institutes
8.3.4. Regulatory Institutes
8.3.5. Others
8.4. Global Biosimulation Market Attractiveness Analysis, by Application
9. Global Biosimulation Market Analysis and Forecast, by Region
9.1. Regional Outlook
9.2. Introduction
9.3. Global Biosimulation Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Biosimulation Market Attractiveness Analysis, by Region
10. North America Biosimulation Market Analysis and Forecast
10.1. Key Findings
10.2. North America Biosimulation Market Value Forecast, by Offering Type, 2018–2030
10.2.1. Software
10.2.1.1. PK/PD Modeling & Simulation
10.2.1.2. PBPK Modeling & Simulation
10.2.1.3. Trial Simulators
10.2.1.4. Molecular Modeling
10.2.1.5. Others
10.2.2. Services
10.3. North America Biosimulation Market Value Forecast, by Application, 2018–2030
10.3.1. Drug Discovery
10.3.1.1. Target Identification & Validation
10.3.1.2. Lead Identification & Optimization
10.3.2. Drug Development
10.3.2.1. Pre-clinical Testing
10.3.2.2. Clinical Trial
10.3.3. Others
10.4. North America Biosimulation Market Value Forecast, by End-user, 2018–2030
10.4.1. Contract Research Organization
10.4.2. Pharmaceutical & Biotechnology Companies
10.4.3. Research Institutes
10.4.4. Regulatory Institutes
10.4.5. Others
10.5. North America Biosimulation Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Biosimulation Market Attractiveness Analysis
10.6.1. By Offering Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Biosimulation Market Analysis and Forecast
11.1. Key Findings
11.2. Europe Biosimulation Market Value Forecast, by Offering Type, 2018–2030
11.2.1. Software
11.2.1.1. PK/PD Modeling & Simulation
11.2.1.2. PBPK Modeling & Simulation
11.2.1.3. Trial Simulators
11.2.1.4. Molecular Modeling
11.2.1.5. Others
11.2.2. Services
11.3. Europe Biosimulation Market Value Forecast, by Application, 2018–2030
11.3.1. Drug Discovery
11.3.1.1. Target Identification & Validation
11.3.1.2. Lead Identification & Optimization
11.3.2. Drug Development
11.3.2.1. Pre-clinical Testing
11.3.2.2. Clinical Trial
11.3.3. Others
11.4. Europe Biosimulation Market Value Forecast, by End-user, 2018–2030
11.4.1. Contract Research Organization
11.4.2. Pharmaceutical & Biotechnology Companies
11.4.3. Research Institutes
11.4.4. Regulatory Institutes
11.4.5. Others
11.5. Europe Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. U.K.
11.5.2. Germany
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Biosimulation Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Material
11.6.3. By Application
11.6.4. By Distribution Channel
11.6.5. By Country/Sub-region
12. Asia Pacific Biosimulation Market Analysis and Forecast
12.1. Key Findings
12.2. Asia Pacific Biosimulation Market Value Forecast, by Offering Type, 2018–2030
12.2.1. Software
12.2.1.1. PK/PD Modeling & Simulation
12.2.1.2. PBPK Modeling & Simulation
12.2.1.3. Trial Simulators
12.2.1.4. Molecular Modeling
12.2.1.5. Others
12.2.2. Services
12.3. Asia Pacific Biosimulation Market Value Forecast, by Application, 2018–2030
12.3.1. Drug Discovery
12.3.1.1. Target Identification & Validation
12.3.1.2. Lead Identification & Optimization
12.3.2. Drug Development
12.3.2.1. Pre-clinical Testing
12.3.2.2. Clinical Trial
12.3.3. Others
12.4. Asia Pacific Biosimulation Market Value Forecast, by End-user, 2018–2030
12.4.1. Contract Research Organization
12.4.2. Pharmaceutical & Biotechnology Companies
12.4.3. Research Institutes
12.4.4. Regulatory Institutes
12.4.5. Others
12.4.6.
12.5. Asia Pacific Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Biosimulation Market Attractiveness Analysis
12.6.1. By Offering Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Biosimulation Market Analysis and Forecast
13.1. Key Findings
13.2. Latin America Biosimulation Market Value Forecast, by Offering Type, 2018–2030
13.2.1. Software
13.2.1.1. PK/PD Modeling & Simulation
13.2.1.2. PBPK Modeling & Simulation
13.2.1.3. Trial Simulators
13.2.1.4. Molecular Modeling
13.2.1.5. Others
13.2.2. Services
13.3. Latin America Biosimulation Market Value Forecast, by Application, 2018–2030
13.3.1. Drug Discovery
13.3.1.1. Target Identification & Validation
13.3.1.2. Lead Identification & Optimization
13.3.2. Drug Development
13.3.2.1. Pre-clinical Testing
13.3.2.2. Clinical Trial
13.3.3. Others
13.4. Latin America Biosimulation Market Value Forecast, by End-user, 2018–2030
13.4.1. Contract Research Organization
13.4.2. Pharmaceutical & Biotechnology Companies
13.4.3. Research Institutes
13.4.4. Regulatory Institutes
13.4.5. Others
13.5. Latin America Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Biosimulation Market Attractiveness Analysis
13.6.1. By Offering Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Biosimulation Market Analysis and Forecast
14.1. Key Findings
14.2. Middle East & Africa Biosimulation Market Value Forecast, by Offering Type, 2018–2030
14.2.1. Software
14.2.1.1. PK/PD Modeling & Simulation
14.2.1.2. PBPK Modeling & Simulation
14.2.1.3. Trial Simulators
14.2.1.4. Molecular Modeling
14.2.1.5. Others
14.2.2. Services
14.3. Middle East & Africa Biosimulation Market Value Forecast, by Application, 2018–2030
14.3.1. Drug Discovery
14.3.1.1. Target Identification & Validation
14.3.1.2. Lead Identification & Optimization
14.3.2. Drug Development
14.3.2.1. Pre-clinical Testing
14.3.2.2. Clinical Trial
14.3.3. Others
14.4. Middle East & Africa Biosimulation Market Value Forecast, by End-user, 2018–2030
14.4.1. Contract Research Organization
14.4.2. Pharmaceutical & Biotechnology Companies
14.4.3. Research Institutes
14.4.4. Regulatory Institutes
14.4.5. Others
14.5. Middle East & Africa Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Biosimulation Market Attractiveness Analysis
14.6.1. By Offering Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Ranking Analysis, by Company, 2019
15.3. Company Profiles
15.3.1. Certara
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Dassault Systèmes S.A.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Schrödinger, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Simulations Plus, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Rhenovia Pharma
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Advanced Chemistry Development, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Insilico Biotechnology AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Physiomics plc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Genedata AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Rosa & Co. LLC.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
List of Tables
Table 01: Global Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2014–2025
Table 02: Global Biosimulation Market Value (US$ Mn) Forecast, by Software, 2014–2025
Table 03: Global Biosimulation Market Value (US$ Mn) Forecast, by Application, 2014–2025
Table 04: Global Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2014–2025
Table 05: Global Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2014–2025
Table 06: Global Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 07: Global Biosimulation Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 08: North America Biosimulation Market Value (US$ Mn) Forecast, by Country, 2019–2030
Table 09: North America Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030
Table 10: North America Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030
Table 11: North America Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030
Table 12: North America Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030
Table 13: North America Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030
Table 14: North America Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030
Table 15: Europe Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030
Table 16: Europe Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030
Table 17: Europe Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030
Table 18: Europe Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030
Table 19: Europe Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030
Table 20: Europe Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030
Table 21: Europe Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030
Table 22: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030
Table 23: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030
Table 24: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030
Table 25: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030
Table 26: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030
Table 27: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030
Table 28: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030
Table 29: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030
Table 30: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030
Table 31: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030
Table 32: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030
Table 33: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030
Table 34: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030
Table 35: Latin America Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030
Table 36: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030
Table 37: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030
Table 38: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030
Table 39: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030
Table 40: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030
Table 41: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030
Table 42: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030
List of Figures
Figure 01: Global Biosimulation Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Biosimulation Market Value Share, by Offering Type, 2019
Figure 03: Global Biosimulation Market Value Share, by Application, 2019
Figure 04: Global Biosimulation Market Value Share, by End-user, 2019
Figure 05: Global Biosimulation Market Value Share, by Region, 2019
Figure 06: Global Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 07: Global Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 08: Global Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 09: Global Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 10: Global Biosimulation Market Revenue (US$ Mn), by Software, 2018–2030
Figure 11: Global Biosimulation Market Revenue (US$ Mn), by Services, 2018–2030
Figure 12: Global Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 13: Global Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 14: Global Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 15: Global Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 16: Global Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 17: Global Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 18: Global Biosimulation Market Value (US$ Mn), by Drug Discovery, 2018–2030
Figure 19: Global Biosimulation Market Value (US$ Mn), by Drug Development, 2018–2030
Figure 20: Global Biosimulation Market Value (US$ Mn), by Others, 2018–2030
Figure 21: Global Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 22: Global Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 23: Global Biosimulation Market Value (US$ Mn), by Contract Research Organization, 2018–2030
Figure 24: Global Biosimulation Market Value (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2018–2030
Figure 25: Global Biosimulation Market Value (US$ Mn), by Research Institutes, 2018–2030
Figure 26: Global Biosimulation Market Value (US$ Mn), by Regulatory Institutes, 2018–2030
Figure 27: Global Biosimulation Market Value (US$ Mn), by Others, 2018–2030
Figure 28: Global Biosimulation Market: Regional Outlook
Figure 29: Global Biosimulation Market Attractiveness Analysis, by Region, 2019 and 2030
Figure 30: Global Biosimulation Market Value Share Analysis, by Region, 2020–2030
Figure 31: North America Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 32: North America Biosimulation Market Value Share Analysis, by Country, 2019 and 2030
Figure 33: North America Biosimulation Market Attractiveness Analysis, by Country, 2019–2030
Figure 34: North America Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 35: North America Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 36: North America Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 37: North America Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 38: North America Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 39: North America Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 40: North America Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 41: North America Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 42: North America Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 43: North America Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 44: North America Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 45: North America Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 46: Europe Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 47: Europe Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 48: Europe Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 49: Europe Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 50: Europe Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 51: Europe Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 52: Europe Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 53: Europe Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 54: Europe Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 55: Europe Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 56: Europe Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 57: Europe Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 58: Europe Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 59: Europe Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 60: Europe Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 61: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 62: Asia Pacific Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 63: Asia Pacific Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 64: Asia Pacific Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 65: Asia Pacific Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 66: Asia Pacific Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 67: Asia Pacific Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 68: Asia Pacific Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 69: Asia Pacific Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 70: Asia Pacific Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 71: Asia Pacific Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 72: Asia Pacific Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 73: Asia Pacific Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 74: Asia Pacific Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 75: Asia Pacific Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 76: Latin America Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 77: Latin America Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 78: Latin America Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 79: Latin America Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 80: Latin America Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 81: Latin America Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 82: Latin America Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 83: Latin America Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 84: Latin America Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 85: Latin America Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 86: Latin America Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 87: Latin America Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 88: Latin America Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 89: Latin America Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 90: Latin America Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 91: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 92: Middle East & Africa Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 93: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030
Figure 94: Middle East & Africa Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030
Figure 95: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030
Figure 96: Middle East & Africa Biosimulation Market Value Share Analysis, by Software, 2019 and 2030
Figure 97: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Software, 2020–2030
Figure 98: Middle East & Africa Biosimulation Market Value Share Analysis, by Application, 2019 and 2030
Figure 99: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Application, 2020–2030
Figure 100: Middle East & Africa Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030
Figure 101: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030
Figure 102: Middle East & Africa Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030
Figure 103: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030
Figure 104: Middle East & Africa Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030
Figure 105: Middle East & Africa Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030
Figure 106: Global Biosimulation Market Analysis, by Top Company Ranking, 2019
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Biosimulation Market Forecast Report, 2020-2030
